CONMED (CNMD)
(Real Time Quote from BATS)
$73.39 USD
-1.37 (-1.83%)
Updated Nov 8, 2024 03:45 PM ET
After-Market: $73.43 +0.04 (0.05%) 4:06 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.39 USD
-1.37 (-1.83%)
Updated Nov 8, 2024 03:45 PM ET
After-Market: $73.43 +0.04 (0.05%) 4:06 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Zacks News
Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4
by Zacks Equity Research
Cryolife (CRY) revenues increase year over year across all geographies and major segments.
Quidel (QDEL) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Quidel's (QDEL) flagship Triage sees strong growth in China in Q4.
Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down
by Zacks Equity Research
In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.
Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines
by Zacks Equity Research
Bio-Techne (TECH) sees increase in revenues across key segments.
Here's Why Investors Should Buy CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED's (CNMD) guidance for 2019 buoys optimism in the stock.
DaVita (DVA) Q4 Earnings Beat and Revenues Miss Estimates
by Zacks Equity Research
DaVita's (DVA) Q4 results gain from increasing dialysis services in and outside the United States.
Medidata (MDSO) Q4 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Medidata (MDSO) gains from solid segmental performance in Q4.
Bruker (BRKR) Q4 Earnings In Line, Margin Growth Strong
by Zacks Equity Research
Bruker (BRKR) witnesses a sturdy organic revenue uptick riding on the strength of Bruker Scientific Instruments (BSI) and BEST segments.
STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q3.
IRADIMED (IRMD) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
IRADIMED (IRMD) reports growth across all operating segments and geographies
Phirbo (PAHC) Q2 Earnings Lag Estimates, Operating Margin Up
by Zacks Equity Research
Phirbo (PAHC) witnesses significant growth in core segment revenues in Q2.
Omnicell (OMCL) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Omnicell (OMCL) steadily benefits from product introductions, strategic alliances and digital conversions.
Cardinal Health (CAH) Surges: Stock Moves 6.8% Higher
by Zacks Equity Research
Cardinal Health (CAH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
LabCorp's (LH) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
LabCorp's (LH) Q4 earnings gain on strength in the Covance Drug Development business.
Cardinal Health (CAH) Beats on Q2 Earnings, Ups FY19 View
by Zacks Equity Research
Cardinal Health's (CAH) Q2 results benefit from strong sales in the Pharmaceutical segment. An upbeat guidance is indicative of brighter prospects.
Haemonetics (HAE) Earnings Top, Revenues Lag Estimates in Q3
by Zacks Equity Research
Haemonetics' (HAE) year-over-year earnings growth in Q3 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
Boston Scientific (BSX) Beats on Q4 Earnings, Margins Dip
by Zacks Equity Research
Boston Scientific (BSX) is leaving no stone unturned to strengthen its core businesses and invest in global markets, which accounted for the uptick in sales across all geographies.
Myriad Genetics (MYGN) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Myriad Genetics (MYGN) Q2 performance by Hereditary Cancer testing is encouraging while GeneSight test revenues disappoint.
Cerner (CERN) Q4 Earnings Meet Estimates, Revenues Miss
by Zacks Equity Research
Cerner (CERN) gains from solid segmental revenues in fourth-quarter 2018. However, the company's 2019 guidance disappoints.
Luminex (LMNX) Q4 Earnings Miss, 2019 Guidance Lacks Luster
by Zacks Equity Research
Luminex (LMNX) gains from core Consumable unit's strong fourth-quarter show.
Becton, Dickinson (BDX) Q1 Earnings In Line With Estimates
by Zacks Equity Research
Strong segmental performance favors Becton, Dickinson's (BDX) fiscal Q1 results.
Omnicell Solid on Geographic Expansion Amid Stiff Competition
by Zacks Equity Research
Omnicell (OMCL) gains from expanding into new markets. Stiff rivalry is a concern.
PerkinElmer (PKI) Q4 Earnings Beat, Diagnostics Grows Y/Y
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter 2018 results gain from solid segmental contributions.
McKesson (MCK) Beats on Q3 Earnings, Gains From Solid View
by Zacks Equity Research
McKesson (MCK) gains from the U.S. Pharmaceutical and Specialty Solutions segment in third-quarter fiscal 2019.
Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Revenues Top
by Zacks Equity Research
Zimmer Biomet (ZBH) sees strength in the Asia Pacific and EMEA regions as well as in the Spine & CMF business in Q4.